Apollo Health Ventures

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.

Bloom Science, Inc. is a biotechnology company focused on developing neuroprotective medicines that leverage the microbiome to address epilepsy and other neurological disorders. Founded in 2017 and based in San Diego, California, the company aims to create genetically optimized microbes that can treat patients suffering from pharmacoresistant and underserved diseases. Bloom Science seeks to translate the therapeutic advantages of the ketogenic diet into innovative biopharmaceuticals, providing effective treatment options for individuals facing serious and life-altering neurological conditions.

Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.

Samsara Therapeutics, Inc. is a biopharmaceutical platform company focused on discovering and developing innovative therapeutics for age-related diseases and unmet medical needs. Founded in 2018 and based in Hamburg, Germany, with additional operations in Oxford, Paris, Graz, and San Diego, the company utilizes a unique geroprotectors screening platform to create caloric restriction mimetic (CRM) molecules. These compounds aim to address the primary molecular causes of aging by targeting essential hallmarks such as proteostasis, autophagy, and energy metabolism. Samsara Therapeutics is recognized for having the largest pipeline dedicated to the identification, chemical optimization, and in vivo validation of compounds that extend healthy lifespan and provide potential treatments for rare genetic and neurodegenerative diseases.

Aeovian Pharmaceuticals is a San Francisco-based biopharmaceutical company focused on the research and development of innovative therapeutics for rare and age-related diseases. Founded in 2012, the company aims to discover and commercialize compounds that modulate key molecular pathways, specifically targeting the mTORC1 and mTORC2 pathways. By addressing the underlying causes of disease initiation and progression—such as oxidative, cellular, and environmental stress—Aeovian Pharmaceuticals seeks to provide effective treatments that improve patient outcomes.

Samsara Therapeutics, Inc. is a biopharmaceutical platform company focused on discovering and developing innovative therapeutics for age-related diseases and unmet medical needs. Founded in 2018 and based in Hamburg, Germany, with additional operations in Oxford, Paris, Graz, and San Diego, the company utilizes a unique geroprotectors screening platform to create caloric restriction mimetic (CRM) molecules. These compounds aim to address the primary molecular causes of aging by targeting essential hallmarks such as proteostasis, autophagy, and energy metabolism. Samsara Therapeutics is recognized for having the largest pipeline dedicated to the identification, chemical optimization, and in vivo validation of compounds that extend healthy lifespan and provide potential treatments for rare genetic and neurodegenerative diseases.

Cleara Biotech B.V. develops compounds for selectively eliminating senescent and senescent like cancer cells. The company develops FOXO4 based anti senescence drugs for countering chemotoxicity and therapy resistant cancer cells. Cleara Biotech B.V. is based in Utrecht, the Netherlands.

Aeovian Pharmaceuticals is a San Francisco-based biopharmaceutical company focused on the research and development of innovative therapeutics for rare and age-related diseases. Founded in 2012, the company aims to discover and commercialize compounds that modulate key molecular pathways, specifically targeting the mTORC1 and mTORC2 pathways. By addressing the underlying causes of disease initiation and progression—such as oxidative, cellular, and environmental stress—Aeovian Pharmaceuticals seeks to provide effective treatments that improve patient outcomes.